Core Viewpoint - The Hong Kong and A-share markets are experiencing positive trends, with the medical device sector showing signs of recovery, particularly in the context of policy optimization and inventory reduction. MicroTech Medical (02235.HK) has reported significant revenue growth and a return to profitability, driven by strong CGM sales, overseas market expansion, and improved operational efficiency [1][12]. Group 1: Market Trends and Opportunities - The medical device sector is benefiting from favorable market conditions, with a bullish outlook for the industry as a whole [1]. - The global diabetes patient population is projected to exceed 589 million in 2024, with China leading in numbers, indicating a growing market for diabetes management solutions [4]. - Continuous Glucose Monitoring (CGM) technology is transforming blood sugar management, offering real-time data and improving patient experiences compared to traditional methods [5]. Group 2: Company Performance and Growth - MicroTech Medical's revenue for 2025 is expected to reach at least 650 million yuan, representing an approximate 88.1% year-on-year increase, with a net profit of over 38 million yuan [12]. - The company has seen robust growth in its core CGM product, with significant international market expansion contributing to its revenue increase [12]. - The reduction in sales and management expenses has improved profitability, marking a transition from a strategic loss phase to a profit-driven growth stage [12]. Group 3: Strategic Advantages - MicroTech Medical is uniquely positioned with a comprehensive product lineup, including both a patch insulin pump and a real-time CGM, providing a full spectrum solution for diabetes management [16]. - The company is exploring AI applications in CGM, enhancing personalized health management services through data analysis [17]. - The increasing share of overseas revenue demonstrates the company's global market capabilities, with potential for further growth in emerging markets [18]. Group 4: Market Valuation and Future Outlook - The recent performance forecast is expected to catalyze a revaluation of MicroTech Medical's stock, supported by its unique product offerings and global growth potential [20]. - Leading brokerages have expressed optimistic views on the company's future, with target prices indicating significant undervaluation compared to global peers [20].

Group 1 - The core point of the article is that the shareholder, Ms. Zeng Hui, has reduced her stake in the company, Saiteng Co., Ltd. (603283.SH), by selling a total of 1.05 million shares, which represents 0.39% of the company's total share capital [1] - Following the share reduction, Ms. Zeng's ownership percentage decreased from 19.24% to 18.85%, indicating a significant change in her equity position [1] - The reduction in shareholding occurred between February 25 and February 26, 2026, through centralized bidding and block trading methods [1]

Core Viewpoint - Jinbo Co., Ltd. reported a significant increase in total operating revenue for the fiscal year 2025, but continued to face substantial losses in various profit metrics [1] Financial Performance - The company achieved total operating revenue of 823 million yuan, representing a year-on-year increase of 53.27% [1] - Operating profit showed a loss of 1.37 billion yuan, compared to a loss of 822 million yuan in the same period last year [1] - Total profit also recorded a loss of 1.376 billion yuan, slightly improved from a loss of 835 million yuan in the previous year [1] - The net profit attributable to shareholders of the parent company was a loss of 1.382 billion yuan, compared to a loss of 815 million yuan in the prior year [1] - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, was a loss of 1.426 billion yuan, worsening from a loss of 848 million yuan in the same period last year [1]

Group 1 - The company announced the resignation of Huang Shikun as executive director, chairman of the board, chairman of the nomination committee, and member of the remuneration committee, effective from February 27, 2026 [1] - Huang Shifeng also resigned as executive director and member of the corporate governance committee, effective from February 27, 2026 [1] - Following the resignations, Tong Jun has been appointed as the chairman of the board, effective from February 27, 2026 [2] Group 2 - Li Jing has been appointed as an independent non-executive director [2]

Core Viewpoint - The company reported a decline in both revenue and net profit for the year 2025, indicating significant challenges in its traditional communication business despite growth in its core network system business [1] Financial Performance - The company achieved an operating revenue of 876.18 million yuan in 2025, a decrease of 7.93% compared to the previous year [1] - The net profit attributable to the parent company was -62.54 million yuan, reflecting a substantial decline of 327.94% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -77.65 million yuan, marking a drastic decrease of 996.98% compared to the same period last year [1] Business Segments - The core network system business experienced growth during the reporting period [1] - The traditional communication business faced significant pressure, contributing to the overall decline in revenue and gross margin [1]

格隆汇2月27日丨周大福创建(00659.HK)宣布，根据债券的条款及条件第8(C)项条件(赎回、购买及注销 －发行人选择赎回)，公司已于2026年2月27日向债券持有人发出通告，表示其将于选择日(即2026年4月 18日)按本金额连同截至选择日(但不包括该日)的应计但未付利息(如有)赎回于该日仍未偿还的全部(而非 仅部分)债券(「余下可换股债券」)。 ...

Core Viewpoint - Lao Heng He Brewing (02226.HK) announced that its public float is approximately 23.27%, which is below the minimum requirement of 25% as per Listing Rule 13.32B(1) [1] Group 1 - The company is currently in discussions with its core connected persons to ascertain their intentions regarding the sale of relevant shares and the expected quantity [1] - The company plans to implement a public float restoration plan according to the indicative timeline provided in the announcement [1] - The company aims to restore its public float by July 23, 2026, or earlier [1]

格隆汇2月27日｜微芯生物公告，董事长XIANPINGLU博士提议公司使用自有资金和自筹资金以集中竞 价交易方式进行股份回购，回购资金总额不低于人民币8000万元（含），不超过人民币1.2亿元 （含），回购价格不高于公司董事会审议通过回购股份方案前30个交易日公司股票交易均价的150%。 ...

Core Viewpoint - The company,卓能(集团)(00131.HK), reported a significant increase in revenue and profitability for the six months ending December 31, 2025, compared to the same period in the previous year, indicating a strong recovery and growth trajectory [1]. Financial Performance - Revenue for the six months ending December 31, 2025, was HKD 272,396,000, a 250.6% increase from HKD 77,685,000 for the same period in 2024 [1]. - Profit attributable to equity holders for the 2025 period was HKD 180 million, compared to a loss of HKD 49.518 million in the 2024 period [1]. - Basic earnings per share for the 2025 period were HKD 0.28, a turnaround from a loss of HKD 0.08 per share in the 2024 period [1]. Equity and Shareholder Value - As of December 31, 2025, the total equity attributable to equity holders was approximately HKD 5,982,035,000, an increase of HKD 210,626,000 or 3.6% from HKD 5,771,409,000 as of June 30, 2025 [1]. - The equity per share attributable to equity holders was HKD 9.17, unchanged from the total number of issued ordinary shares of 652,676,781 [1].

Group 1 - Tianyuan Medical (00557.HK) announced the appointment of Li Bizhi as the company secretary, effective from February 27, 2026, replacing Xiao Wen'an [1] - Xiao Wen'an has submitted his resignation as the company secretary, effective from the same date [1]